List of Contract Research Companies with Phase 4 Active Clinical Trial - 16

BioCytics via the Human Applications Lab is focused on bringing personalized oncology treatments to the market. BioCytics has an ongoing IRB-approved clinical trial (BioCytics 0001; NCT00571389) that allows for the collection and study of blood and tissue samples from consenting cancer patients. We are incubated within Carolina BioOncology - a preferred cancer treatment and Phase I drug testing facility. BioCytics was founded by Dr. John Powderly, MD, medical board certified oncologist and a certified physician investigator (CPI), who is also president of Carolina BioOncology Institute (CBOI).

Eleva is a clinical-stage biopharmaceutical company unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform. The company’s proprietary drug development activities currently focus on complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant version of human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. The company’s aGal (RPV-001) program to treat Fabry disease has completed a Phase 1b clinical study with promising results. All programs are sourced from Eleva’s transformative moss-based expression system, which allows lab to GMP-scale manufacturing of challenging proteins with previously untapped therapeutic potential.

Eurofins Advinus Private Limited is a premier contract research, development and manufacturing organization (CRDMO) serving diverse industries to help advance their R&D programs within defined timelines with highest level of quality. With 30+ years of GLP experience, we have a proven track record of successfully delivering many integrated and stand-alone projects to meet our partner’s requirements. We offer a complete suite of drug discovery and development services. Our drug discovery services include medicinal and synthetic chemistry, ADMET/DMPK and Discovery Biology across various therapeutic areas. Our preclinical development services include process development, DMPK and safety assessment for developing full CMC & Pharmtox packages towards IND submissions. Our team has immense experience with NDA-enabling studies. Data from our labs has been successfully submitted and approved by various regulatory authorities. We have a track record of 90+ INDs, 65+ carcinogenicity studies, 25,000+ regulatory studies. We offer biocompatibility testing services for medical devices. We have in-house expertise for bioanalytical assay development and validation services in accordance with USFDA and EMA guidelines for Novel Chemical Entities (NCEs), Novel Biological Entities (NBEs) and Biosimilars. We support drug substance requirements from multi kilogram to multi-ton scale for preclinical toxicology studies, clinical trials and commercial manufacturing. We manufacture RSMs, advanced-intermediates, APIs and NCEs. We provide seamless transition from candidate selection to commercialization. In the last 5 years, we have completed 100+GMP campaigns. For the Agrochemical sector, we offer product development services to support global regulatory submissions. We have successfully executed studies following all international guidelines. We offer a wide range of field and lab trials to the manufacturers of Agricultural inputs, like pesticides, biopesticides, and fertilizer.

Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients. Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing. We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI. We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.

Biologics, Small Molecules

ICON works to accelerate the development of live-saving drugs and devices by providing a wide range of consulting, development, and commercialization services.

Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical data. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize effect detection in clinical research.

Lindus Health is an anti-CRO running radically faster, more reliable clinical trials for life science pioneers – bringing ground-breaking treatments to patients more quickly. This is achieved through a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), a world-class clinical operations team with its unique software platform, and access to over 40 million Electronic Health Records. Clinical trials are the biggest bottleneck to advances in healthcare. Lindus Health removes this constraint through end-to-end execution of clinical studies driven by technology and forward-thinking approaches to clinical operations.To date, Lindus Health has delivered clinical trials across the US, UK and Europe to tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over $80M from investors including Peter Thiel, Balderton, Creandum, Firstminute Capital, and Seedcamp.

Massive Bio collects and curates the latest scientific knowledge in genomics of cancer, connects with clinical information incorporate all new discoveries in treatment plans.

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 5,800 people across 43 countries.

4Clinics is a Contract Research Organization (CRO) providing Data management, Biostatistics, Scientific Writing, Regulatory Affairs and Clinical Operations services for clinical and epidemiological studies with a particular expertise in vaccines, immunology, immuno-oncology and medical devices. 4Clinics serves pharmaceutical, biotechnology and medical devices companies as well as NGOs, hospitals and researchers with tailor-made services including remote biometry and medical writing platforms. 4Clinics has offices in Belgium, France and Morocco and has a global coverage. For more information, please visit www.4Clinics.com

Pace® Science and Technology Company makes the world a safer, healthier place. We partner with clients to provide the service, science, and laboratory data needed to make critical decisions that benefit us all. Through a nationwide laboratory network, Pace® advances the science of businesses, industries, consulting firms, government agencies, and others. ANALYTICAL SERVICES Pace® Analytical Services is a division of Pace® Science and Technology, providing local testing and analytical services backed by a large, national laboratory and service center network. Through in-lab, mobile, and emergency onsite containment and regulatory services, we ensure our air, water, soil, and more are safe for our communities and lives. LIFE SCIENCES Pace® Life Sciences is a division of Pace® Science and Technology committed to advancing the science of the pharmaceutical and biopharmaceutical industry by providing full-service CDMO/CRO capabilities and professional services for in-house labs through a nationwide network of service centers, manufacturing sites, and FDA-registered laboratories. COMMITMENT We believe the work our customers do is important to improving our communities and lives and are committed to supporting them through strong partnerships, delivering upon expectations, and providing exceptional customer service.

Perceptive Inc. is a global technology-enabled service provider dedicated to the biopharmaceutical industry. Recently rebranded as "Perceptive," the company focuses on advancing life-changing treatments through innovative services and solutions. Perceptive offers a range of services, including Perceptive Discovery, which aids in preclinical and first-in-human imaging to identify promising compounds. The Perceptive eClinical division enhances patient and clinical supply management, featuring services like Randomization & Trial Supply Management and Interactive Response Technology. Additionally, Perceptive Imaging provides expertise in scientific, regulatory, and operational aspects to support efficient data collection in clinical trials. With a client base that includes many leading pharmaceutical and biotech companies, Perceptive operates globally, ensuring smooth execution of clinical trials across various regions. The company has played a significant role in supporting nearly 12,000 clinical research trials and over 800 approvals, particularly in oncology and neuroscience, while upholding values of customer-centricity, quality, and accountability.

Rubix LS: The Health Outcomes Architect At Rubix LS, we drive innovation in clinical research, drug development, and public health by combining cutting-edge science, real-world data, and inclusive patient engagement. Our work is structured around three core pillars: 🔹 Investigator-Led Research – We conduct our own research and develop targeted solutions to accelerate new therapies and improve health outcomes. 🔹 Clinical Research Services – We collaborate with biotech, pharma, and life sciences companies to manage clinical trials, support regulatory submissions, and enhance patient diversity in research. Our work is powered by 18M patient data sets and 369M patient data points. 🔹 Government & Public Health – We partner with federal agencies and public health organizations to develop policies, improve disease surveillance, and advance health equity through data-driven solutions. Leveraging Environmental & Geographic Insights To better understand health risks and intervention strategies, we integrate: ✅ DoE data to analyze long-term environmental exposures. ✅ USDA data to study the impact of food and nutrition on health. ✅ Heat Sink data to model cancer risk and environmental disease patterns. At Rubix LS, we don't just conduct research—we build pathways to better health by ensuring therapies are developed, tested, and delivered with precision, equity, and impact. 🔗 Learn more at our website.

Science 37's mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Metasite™ and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration.

Yuhan Corporation is an integrated healthcare company founded in 1926. It has achieved top market value and sales revenue in Korean pharmaceutical industries, and been awarded for the most respected and trusted company in Korea for recent 11 consecutive years. It has two subsidiaries, Yuhan Chemical and Yuhan Medica, and the affiliates including Joint Ventures with Janssen(Belgium), the Clorox Company(USA), and Kimbery-Clark Corporation(USA). The core business of Yuhan can be classified into Primary & Specialty care, Dietary supplement, Household & Animal care, and contract manufacturing of active pharmaceutical ingredients.